RheumNow

Day 1 Recap: #ACR25 Highlights Join RheumNow Faculty Drs. Aurelie Najm, Yuz Yusof, Janet Pope and Jack Cush as they

CAR T Which cells to target What patients & what disease When is right time In vivo (new) ex vivo

Prospective RCT on safety & efficacy of TAC+GC vs. MMF+GC TAC+GC was comparable to MMF+GC as continuous induction m https://pbs.twimg.com/profile_images/1027501556868870145/2culK0bN_normal.jpg

Needle in a haystack What T cell to target for #autoimmune diseases T cell repetoires (TCR) not all are sequenced

Toxicity is the big question about CAR-T in RA – what did the CRS/ICANS profile look like in this German

So what’s been tried for ICANS, knowing that it’s unlikely that one therapy will fix all of it? @CarolineDiorio @Childr

What does the FDA regulatory approach look like for CAR-T and T cell engages right now? The FDA session at

2465: Dual-target CD19/BCMA CAR-T in refractory SLE (Phase 1) 🔹All pts (n=10) met SRI-4 by wk24 🔹DORIS remission: https://pbs.twimg.com/profile_images/1590198200824000512/8_JyVKFt_normal.jpg john+RNV2@john…

LB23: Regulate-RA- ongoing Phase 1 trial of autologous CAR-Tregs in refractory RA (no lymphodepletion) 🔹 4/6 pts had https://pbs.twimg.com/profile_images/1590198200824000512/8_JyVKFt_normal.jpg john+RNV2@john…

LB04: Another approach to CAR-T, CD20+/BCMA bispecific CAR-T in refractory proliferative LN: 🔹100% discontinued biolo https://pbs.twimg.com/profile_images/1590198200824000512/8_JyVKFt_normal.jpg john+RNV2@john… Thu, 10/30/2025 –

Andrew Yee @andrew02114 of @MGHCancerCenter details out how quickly the CAR-T paradigm changed in myeloma/lymphoma – fro https://pbs.twimg.com/profile_images/1659729373426241536/tnA2hRe4_normal.jpg john+RNV2@john… Thu,

Rheum Now Rheumatology Round-Up — LIVE Join Drs. Jack Cush & Arthur Kavanaugh for this livestream with two of rheu

#SLE #DORIS #remission is RARE and without #prednisone even rarer #ASIA #Pacific 5K pts over 10 yrs A call to

What to use in future for active #Sjogren’s #SjD B cell depletion, signal attenuation Ianalumab 2+ phase3 RCTs Telitacep https://pbs.twimg.com/profile_images/1007774150000332801/SjLeJk3G_normal.jpg

#Urinary #biomarkers #lupus #nephritis #Tenascin C -suggests repair, fibrosis, progress of #LN #IL16, #CD163, & mor https://pbs.twimg.com/profile_images/1007774150000332801/SjLeJk3G_normal.jpg john+RNV2@john… Thu, 10/30/2025

#MTX is NOT the same as TCZ in #GCA in RCT #TCZ did better So use an advanced Rx for

Will #PAD4 levels predict pts w #CCP positive #arthralgia who will develop #RA? Leeds study – 79 at risk pts

What happens if you have #axSpA & concomitant #FM? Pts with both have less TNFi retention, -residual pain may lead

#GCA & #PMR @ACRheum #ACR25 #gamechangers #ACRBest Yr 2 Select-GCA abst#776 #upadacitinib in yr2 of GCA REDUCES flar https://pbs.twimg.com/profile_images/1007774150000332801/SjLeJk3G_normal.jpg john+RNV2@john…

Post-CAR-T myelopathy has been an issue in heme onc, and is still an unpredictable quantity without a clear cause. Will

When should you order a renal bx in suspected #LN? Active urinary sediment Used to be #UPCR 500g/g or more

Next Generation T-Cell Engager: The Future Dr. Alfred Kim reviews abstract 0001 presented at #ACR25. https://t.co/vmZ https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Wed, 10/29/2025

RheumNow’s expanded coverage of the #ACR25 meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All covera https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john…

CAR-T Cell Therapies Show Promise for Autoimmune Disease Two pioneering studies presented at #ACR25 spotlight the poten https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Wed,